Jiangsu Hengrui Pharmaceuticals (600276.SH): The application for marketing authorization of Ripretinib injection has been accepted.

Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., has received the "Acceptance Notice" issued by the National Medical Products Administration, stating that the application for the marketing authorization of its Replaglutide injection has been accepted by the National Medical Products Administration. The proposed indication for this drug is for blood sugar control in adult patients with type 2 diabetes. It is reported that Replaglutide is a dual agonist of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) independently developed by the company. It can promote insulin secretion, enhance insulin sensitivity, suppress appetite, and regulate glucose and lipid metabolism in the body, thereby improving blood sugar levels and reducing weight. Currently, globally, there is only one drug targeting T2DM of the same mechanism, Eli Lilly's tirzepatide injection (brand name: Mounjaro), which was approved for marketing in the United States in May 2022 and is expected to be approved in the domestic market (brand name: Mufengda) in May 2024. According to the EvaluatePharma database, the global sales revenue of Mounjaro is projected to be approximately $22.965 billion by 2025. So far, the cumulative R&D investment in the Replaglutide-related project has reached about 746 million yuan (unaudited).